Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma

Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor

(2015) Paola Corazao-Rozas et al.   Oncotarget

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma

(2014) Edward J. Hartsough et al.   MOLECULAR CANCER RESEARCH

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Melanoma—the run of success continues

(2014) Dirk Schadendorf et al.   Nature Reviews Clinical Oncology

Directed Phenotype Switching as an Effective Antimelanoma Strategy

(2013) Magalí Sáez-Ayala et al.   CANCER CELL

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

(2013) Rizwan Haq et al.   CANCER CELL

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression

(2013) E. Romano et al.   CLINICAL CANCER RESEARCH

Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

(2013) K. L. Nathanson et al.   CLINICAL CANCER RESEARCH

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

(2013) Ethan V. Abel et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

(2013) Kerstin Trunzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib Induces Senescence Features in Melanoma Cells

(2013) Sebastian Haferkamp et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Resistance to RAF Inhibitors Revisited

(2013) Edward Hartsough et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma

(2013) P. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

(2013) Jessie Villanueva et al.   Cell Reports

Inactivation of the HIF-1 /PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants

(2012) J. Kluza et al.   CANCER RESEARCH

BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma

(2012) Y Shao et al.   CELL DEATH AND DIFFERENTIATION

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

(2012) Kavitha Gowrishankar et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic classification of melanoma cells by phenotype-specific gene expression mapping

(2012) Daniel S. Widmer et al.   Pigment Cell & Melanoma Research

The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer

(2012) Geoffrey D. Girnun   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

(2012) Hubing Shi et al.   Cancer Discovery

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

(2011) F. Su et al.   CANCER RESEARCH

Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition

(2011) H. Shi et al.   CANCER RESEARCH

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells

(2011) Y Cheli et al.   ONCOGENE

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

(2011) Y Cheli et al.   ONCOGENE

Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma?

(2010) Caroline Jose et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

Metabolic flexibility and cell hierarchy in metastatic cancer

(2010) Michael V. Berridge et al.   MITOCHONDRION

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer stem cells versus phenotype-switching in melanoma

(2010) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes

(2010) A. J. Levine et al.   SCIENCE

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH